A Long-Term Safety and Efficacy Study AGN-19920 in Patients With Persistent Erythema Associated With Rosacea

Study Identifier
199201-006
CT.gov Identifier
NCT02095158
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Dermatology - Other
    • Study Drug
  • Oxymetazoline HCL Cream 1.0%
    • Phase
    Phase 3
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    -Moderate to severe persistent facial erythema associated with rosacea.
    Exclusion Criteria:
    * Current treatment with monoamine oxidase (MAO) inhibitors * Raynaud's syndrome, narrow angle glaucoma, orthostatic hypotension, scleroderma or Sjogren's syndrome.

    Protocol Summary

    This study will evaluate the long-term safety and efficacy of oxymetazoline hydrogen chloride (HCL) Cream 1.0% (AGN-199201) in patients with persistent erythema associated with rosacea.

    Study Locations

    Location
    Status
    Location
    Portland, Oregon, United States
    Status
    Not applicable